CAS: 1239-29-8; Furazabol

该化合物是一种合成代谢类类类化合物,即17-丙烯酸类固醇,其特点是对睾丸酮结构的修改,该结构增强了其新陈性质,同时减少了其诱因效应;Furazabol以其促进肌肉生长和改善体能的能力而著称,因为它能够促进肌肉生长和改善体能,使其对医疗和运动环境都感兴趣;该化合物一般是口服的,并因其与其他代谢类固醇相比毒性相对较低而得到承认;然而,它也与潜在的副作用有关,包括荷尔蒙不平衡和肝脏紧张,特别是长期使用;Furazabol由于其性能增强效应,被归类为许多体育组织禁止的物质;它的使用也在许多国家受到管制,反映了对在竞争性体育中安全和伦理影响的关切;

结构式图片

MSDS等安全信息

    上下游产品

    17β-hydroxy-17α-methyl-(5α)-androstane-2,3-dione dioxime mestanolone 17β-Hydroxy-17α-methyl-androstan-2,3-dion 2-Hydroxylimino-17β-hydroxy-17α-methyl-androstan-3-onc][1,2,5]oxadiazole17α-methyl-17β-(3-phenyl-propionyloxy)-(5α)-androstano[2,3-c][1,2,5]oxadiazole

    合成工艺路线路线简述

      📜美雄诺龙置于氢氧化钾,盐酸羟胺,Potassium Tert-Butylate,亚硝酸异戊酯体系中,用 乙二醇,叔丁醇 用作溶剂,化学反应生成夫拉扎勃
      参考文献:有关类固醇的研究.Iv.雄甾烷[2,3-C]呋喃丹及其相关化合物的合成.
      标题:有关类固醇的研究.Iv.雄甾烷[2,3-C]呋喃丹及其相关化合物的合成.
      摘要:合成了与2,3-位融合的呋噁环类固醇.通过2-羟基亚氨基-3-酮(iv)或2,3-二酮(II)从雄甾-3-酮(i)制备的2,3-二羟基亚氨基雄甾烷(III),在碱,琥珀酸酸酐或氯化亚硫酰的作用下,直接环化生成雄甾烷[2,3-C]呋噁烷(xvii).或者,将2,3-二羟基亚氨基化合物(III)用次氯酸钠或四乙酸铅处理,得到相应的呋噁烷n-氧化物(呋氧烷)(xxi),再通过与三乙基磷酸酯加热处理去氧化为呋噁烷(xvii).同样,合成了雄甾-4-烯和雄甾-4,6-二烯[2,3-C]呋噁烷(xvii,Xix).还描述了其衍生物的合成.
      Doi:10.1248/cpb.13.1445

      海关参考信息

      专利信息


      专利号:US-10925977-B2
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
      发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
      权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
      摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

      专利号:KR-101513003-B1
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy compositions and applications

      专利号:US-10814013-B2
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

      专利号:AU-2007308022-A2
      优先权日:2006-10-05
      标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

      专利号:AU-2007308022-A1
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

      专利号:US-2008107598-A1
      优先权日:2006-10-05
      标 题:Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      合成参考文献


      摘要:Chemical and Pharmaceutical Bulletin., 14(285), 1966 []
      摘要:Kiso to Rinsho. Clinical Report., 4(2031), 1970
      摘要:21 CFR Sections 1308.11-1308.15 https://www.ecfr.gov/current/title-21/chapter-II/part-1308
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知